3D gait analysis and L-DOPA in Dravet syndrome.

3D gait analysis and effectiveness of L-DOPA on pathological gait in Dravet syndrome.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041190116

Enrollment

Registered

2020-02-17

Start date

2020-02-17

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dravet syndrome(severe myoclonic epilepsy in infant) Dravet syndrome, severe myoclonic epilepsy in infant

Interventions

Arm A:0) 3D gait analysis and RS-fMRI before medication 1) levodopa/carbidopa(5mg/kg/day or 300mg/day(more than 60kg)) given orally during 4-6weeks 2) second 3D gait analysis and RS-fMRI 3) reduce and

D007980

levodopa/carbidopa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.clinically diagnosed with Dravet syndrome 2.6 years or older, exhibiting gait deviations 3.adequately participation to 3D gait analysis with independent walk 4.written informed consent

Exclusion criteria

Exclusion criteria: 1.unnable to participate to 3D gait analysis adequately 2.past prescription of L-DOPA 3.contraindication for L-DOPA 4.severe general complications 5.cannnot obtain informed consent

Design outcomes

Primary

Measure	Time frame
Gait Deviation Index at before and after L-DOPA administration	—

Secondary

Measure	Time frame
Gait Profile Score, gait ability and QOL assessed by questionnaire at before and after L-DOPA administration UPDRS score, FMDRS score functional connectivities of basal ganglia network before and after L-DOPA adminiatration	—

Contacts

Public ContactYuji Ito

Nagoya University Graduate School of Medicine

yuji.ito@med.nagoya-u.ac.jp+81-52-744-2294

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026